Hypofractionated radiotherapy for intermediate-risk head and neck cancer
Part of Cancer clinical trials.
This study tests a shorter course of radiation therapy (called hypofractionated radiotherapy) for people with head and neck cancer who have already had surgery to remove the tumor. It is for patients with certain 'intermediate-risk' features, aiming to improve outcomes while possibly reducing treatment time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had surgery to remove the cancer and lymph nodes in the neck, with all visible cancer removed (R0 resection) and a neck dissection.
- Your pathology report shows clear surgical margins (no cancer cells at the edge of the removed tissue) and no cancer spread outside the lymph nodes (no extranodal extension).
- You have at least one 'intermediate-risk factor' such as close margins (less than 5 mm), tumor stage T3 or T4, lymph nodes stage N2, cancer in lymph or blood vessels, cancer around nerves, poorly differentiated cells, or for oral cavity cancer, a tumor depth over 5 mm.
- Your organ function is adequate, as shown by blood tests (e.g., white blood cells, platelets, hemoglobin).
- You have not had radiation therapy or surgery to the head or neck previously, and you have no other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation therapy (hypofractionated radiotherapy) specifically for older adults with head and neck cancer that has not spread. The aim is to make treatment more convenient and manageable while still being effective, potentially with fewer side effects.
This trial tests whether giving a slightly different schedule of radiation (more frequent, smaller doses) can improve treatment for people with large head and neck cancers. It is for patients who are getting radiation as their main treatment, sometimes with chemotherapy as well.
This trial looks at whether giving less (de-escalated) radiation after surgery is as effective and safer for people with locally advanced head and neck squamous cell carcinoma who had a strong response to treatment before surgery. If you had no remaining cancer or only very small amounts of cancer left in the surgical specimen, this approach may help reduce side effects while keeping control of the disease.
This Phase 2 trial tests a specific, shorter type of focused radiation to help relieve symptoms from head and neck squamous cell carcinoma. It compares two radiation timing/planning approaches to see which better improves comfort and quality of life.
This study looks at using a special scan (F-MISO-PET) to see areas of low oxygen in head and neck cancer. The radiation dose is then customized to give higher doses to those low-oxygen areas, which may improve the chance of controlling the tumor.
This study tests whether adding two different drugs (nimotuzumab and benmelstobart) to standard radiation therapy after surgery can help improve outcomes for people with intermediate-risk head and neck cancer. It looks at whether the combination slows cancer growth or reduces the chances of it coming back.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.